1. FOUNDER, SCIENTIFIC DIRECTORTM
ISTVAN PETAK, MD, PHD
FOUNDER, SCIENTIFIC DIRECTOR

2. 7,6 MILLION
13,1 MILLION
1:4
GLOBOCAN 2008, WHO

3. Which are the drugable gene mutations?
Growth factor
Growth Factor Receptor
Tyrosin kinases A
Mutant Gene
Census
Nucleus
Faulty signal
transduction
protein
Cancer Cell
Targeted drug
Division

4. Biomedical RESEARCHERS trained in the usa and swiss
Story of kps (2003)
Biomedical RESEARCHERS trained in the usa and swiss
1995 => 2002
Dr. ISTVAN PETAK
USA
Dr. RICHARD SCHWAB
SWISS

5. Story of kps (2004)
First molecular diagnostics based targeted tHerapy of a LUNG CANCER PATIENT
2003
2004
2009
Schwab Richárd, Peták István, Pintér Ferenc….Kopper László, Kéri György, Pap Ákos
J Clin Oncol Oct 20;23(30):

6. MOLECULAR DIAGNOSTIC LABORATORY

7. PATENTED TECHNOLOGY TO ANALYZE SMALL SAMPLES
100%
MULTIPLEX
XS-dXtm
OPTIMIZED
DIRECT PCR
LCM (ZEISS-PALM)

8. Successful diagnostics in 84 cells
(italian patient)
28 db
56 db
EGFR EXON 21
L858R
Response to therapy

9. INTERNATIONAL EXPANSION WITH THE SUPPORT OF VENTURE CAPITAL INVESTMENT IN 2012

10. 500,000 mutations in 460 cAncer genes
SANGER DATABASE
460 cancer genes
1% of all genes
90% somatic mutations
20% germline mutations
10% show both somatic and germline mutations

11. TARGETED THERAPIES IN PIPELINES
Abbott Astra-Z GSK Lilly Merck Novartis Pfizer Roche Wyeth
EGFR x x
VEGF/R x x
IGF/R x x x
cMET x x x x
Multi x x x x x x
PI3K/mTOR x x x x x
RAF x x x
MEK x x
SRC x x
CDK4/ x
CHK1 x x
Aurorakináz x x x
Eg5,kinezin x
Tubulin x x
PARP x x x
BCL2 x
IAP x
Survivin x
HSP90 x x
Deacetiláz x
Endotelin x x
g-szekretáz x x
MDM x
DKK x
5a-reduktáz x
VDA x
Bali
2010. Október 6.
11. dia 11

12. 5000< CLINICAL TRIALS FOR BREAST CANCER (WWW.CLINICALTRIALS.GOV)
MORE AND MORE BIOMARKER DRIVEN LOOKING FOR SMALL FRACTION OF PATIENTS

13. MOLECULAR TARGETS
…50 ….
CLINICAL PARAMETERS

14. PIONEERING NEXT GENERATION SEQUENCING IN ONCOLOGY

15. „HeurAA” Heuristic Amplicon Analyzer
PATENTED TECHNOLOGY TO find mutations
IN MANY SEQUENCES
„HeurAA” Heuristic Amplicon Analyzer

16. Number of genes
number
2009
2010
2011
2012

17. TARGETED RESEQUENCING PANELS
58 genes
ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNAS, HNF1A, HRAS, IDH1, JAK2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL.+ egyedi gének +
FISH:
EGFR, HER-2, FGFR, ALK, MET
Illumina HiSeq™ 2000 platform for 2574 exons representing 176 genes captured using Agilent SureSelect™
50% acionable mutations
MGH's Diagnostic Molecular Pathology lab
SNaPshot assay, hotspot mutations in 14 oncogenes
50 to 60 patients per week
NEXT: NGS 50 different targets
Genomweb September 19, 2012 +
in combination with fluorescence in situ hybridization
Feri Dia next gen Messechusec 15 gén átállás
Ilimuna, roche, Foundation med, diagnostics

18. MOLECULAR GENETICS BASED PERSONALIZED SIGNAL TRANSDUCTION THERAPIES
GENE TEST
58<
TARGET
280<
TARGETED DRUGS
CANCER CELLS

19. ONCOMPASS TM IS A “BLUE OCEAN” SERVICE IN A RAPIDLY GROWING MARKET
OUR COSTUMERS:
PATIENTS: THEY WANT ACCESS TO MORE EFFECTIVE AND LESS TOXIC TARGETED THERAPY
PHARMA: THEY WANT TO FIND PATIENTS WITH RARE GENETIC PROFILE MATCHING THEIR DRUG PHARMA/CRO: THEY WANT TO RECRUIT PATIENTS WITH RARE GENETIC PROFILE TO ACCELERATE
DOCTORS/HOSPITALS: THEY WANT MORE PATIENTS, CLINICAL TRIALS ARE PROFITABLE AND COMPETITIVE
PAYERS/INSURANCE: THEY WANT MORE COST EFFECTIVE TREATMENT, THEY WANT MORE PATIENTS IN CLINICAL TRIALS

20. ONCOMPASS TM IS A “BLUE OCEAN” SERVICE
IN A RAPIDLY GROWING MARKET IN THE NEXT 20 YEARS
ENGINES OF GROWTH:
PATIENTS: THE NUMBER WILL 2X IN THE NEXT 20 YEARS (INCREASE WILL BE FASTER IN ASIA)
DRUGS: THE NUMBER OF TARGETED DRUGS WILL 10X
GENES: NUMBER OF GENES ANALYZED ON ONE CHIP WILL 10X

21. THANK YOU FOR YOUR KIND ATTENTION!